Australia - engelsk - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - mycophenolate mofetil, quantity: 500 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; purified talc; povidone; microcrystalline cellulose; magnesium stearate; titanium dioxide; hypromellose; indigo carmine; hyprolose; iron oxide red; macrogol 400 - cellcept is indicated for the prophylaxis of solid organ rejection in adults receiving allogeneic organ transplants. cellcept is indicated for the prophylaxis of organ rejection in paediatric patients (2 to 18 years) receiving allogeneic renal transplants.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - mycophenolate mofetil, quantity: 250 mg - capsule, hard - excipient ingredients: povidone; titanium dioxide; iron oxide yellow; iron oxide red; croscarmellose sodium; gelatin; pregelatinised maize starch; indigo carmine; magnesium stearate - cellcept is indicated for the prophylaxis of solid organ rejection in adults receiving allogeneic organ transplants. cellcept is indicated for the prophylaxis of organ rejection in paediatric patients (2 to 18 years) receiving allogeneic renal transplants.

Israel - engelsk - Ministry of Health

roche pharmaceuticals (israel) ltd - mycophenolate mofetil - capsules - mycophenolate mofetil 250 mg - mycophenolic acid - mycophenolic acid - prophylaxis of rejection in renal allograft recepients, and in patients reciving allogenic cardiac transplants. cellcept should be used concomitantly with cyclosporin and corticosteroids.allogenic hepatic transplant.

Israel - engelsk - Ministry of Health

roche pharmaceuticals (israel) ltd - mycophenolate mofetil - film coated tablets - mycophenolate mofetil 500 mg - mycophenolic acid - mycophenolic acid - prophylaxis of rejection in renal allograft recepients, and in patients reciving allogenic cardiac transplants. cellcept should be used concomitantly with cyclosporin and corticosteroids.allogenic hepatic transplant.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - mycophenolate mofetil, quantity: 200 mg/ml - suspension - excipient ingredients: citric acid; xanthan gum; aspartame; methyl hydroxybenzoate; purified water; silicon dioxide; sorbitol; lecithin; sodium citrate dihydrate; flavour - cellcept is indicated for the prophylaxis of solid organ rejection in adults receiving allogeneic organ transplants. cellcept is indicated for the prophylaxis of organ rejection in paediatric patients (2 to 18 years) receiving allogeneic renal transplants.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - mycophenolate mofetil, quantity: 500 mg - injection, powder for - excipient ingredients: polysorbate 80; sodium hydroxide; citric acid; hydrochloric acid - cellcept is indicated for the prophylaxis of solid organ rejection in adults receiving allogeneic organ transplants. cellcept is indicated for the prophylaxis of organ rejection in paediatric patients (2 to 18 years) receiving allogeneic renal transplants.

Israel - engelsk - Ministry of Health

roche pharmaceuticals (israel) ltd - mycophenolate mofetil - film coated tablets - mycophenolate mofetil 500 mg - mycophenolic acid - prophylaxis of rejection in renal allograft recepients, and in patients reciving allogenic cardiac transplants. cellcept should be used concomitantly with cyclosporin and corticosteroids.allogenic hepatic transplant.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - mycophenolate mofetil 250mg;   - capsule - 250 mg - active: mycophenolate mofetil 250mg   excipient: croscarmellose sodium gelatin magnesium stearate povidone pregelatinised maize starch - cellcept is indicated for the prophylaxis of solid organ rejection in adults receiving allogeneic organ transplants. cellcept is indicated for the prophylaxis of organ rejection in paediatric patients (2 to 18 years) receiving allogeneic renal transplants.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - mycophenolate mofetil 500mg (as 542 mg of the hydrochloride salt);   - powder for infusion - 500 mg - active: mycophenolate mofetil 500mg (as 542 mg of the hydrochloride salt)   excipient: citric acid polysorbate 80 sodium chloride - cellcept is indicated for the prophylaxis of solid organ rejection in adults receiving allogeneic organ transplants. cellcept is indicated for the prophylaxis of organ rejection in paediatric patients (2 to 18 years) receiving allogeneic renal transplants.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - mycophenolate mofetil 200 mg/ml;   - powder for oral suspension - 200 mg/ml - active: mycophenolate mofetil 200 mg/ml   excipient: aspartame citric acid colloidal silicon dioxide fruit mix flavour 274869 lecithin methyl hydroxybenzoate sodium citrate dihydrate sorbitol xanthan gum - cellcept is indicated for the prophylaxis of solid organ rejection in adults receiving allogeneic organ transplants. cellcept is indicated for the prophylaxis of organ rejection in paediatric patients (2 to 18 years) receiving allogeneic renal transplants.